Top Health Tech Companies in Melbourne (61)
For more than two decades, Imprivata has been redefining how life- and mission-critical industries secure and manage digital identities. We empower healthcare and enterprise organizations to enable fast, compliant, and secure access to technology—allowing clinicians and staff to stay focused on what matters most: patient care and operational excellence. Our digital identity platform is purpose-built for complex environments where every second...
Imprivata's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is described as sizable and growing rapidly, with independent reporting and credit analyses pointing to continued double‑digit expansion. ARR and ACV are characterized as increasing consistently since 2022.
Customer Loyalty & Retention: Retention is depicted as very high, with consistent expansion within existing accounts that supports sustained recurring revenue growth. Commentary highlights strong share‑of‑wallet gains and durable renewals across healthcare customers.
Product Line Growth: The portfolio has broadened through repeated acquisitions (e.g., SecureLink, Verosint) and new capabilities such as passwordless authentication and agentic identity management. These moves signal active investment to expand addressable use cases and deepen the platform.
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.
Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.
Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.
PKG Health believes every person with a neurological condition deserves to live their best life every day. We leverage the world’s largest body of clinical evidence in neurology, to create and deliver precision medicine by accelerating the research, approval and adoption of treatments. Its lead product, the Parkinson's KinetiGraph®(PKG® or Personal KinetiGraph® in the US), has been developed by neurologists...
The Royal Australasian College of Surgeons (RACS) is a nonprofit professional body for surgeons in Australia and New Zealand. It trains and assesses surgical trainees, awards specialist qualifications, supports continuing professional development, and promotes high standards of surgical care, professionalism and education. RACS also advocates for surgical standards, represents the surgical fellowship, and provides public information about surgery and qualified...
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to...
Moderna's Top Stability & Growth Strengths
Innovation-Driven Growth: The company is positioned as a leader in mRNA medicine with multiple late-stage respiratory and oncology programs that could expand beyond COVID into new indications. Acceptance of the flu BLA and positive Phase 3 data for a flu+COVID combo create concrete approval catalysts that could broaden the seasonal franchise if reviews are favorable.
Product Line Growth: The business is transitioning from a single declining product toward a multi-product portfolio, with RSV, next-gen COVID, flu, and combo vaccines advancing toward targeted 2026 approvals. Management’s expectation of modest revenue growth in 2026, with no flu or flu/COVID revenue assumed, implies potential upside if launches land on time.
Strong Market Position & Advantage: The company has demonstrated platform leadership by scaling mRNA globally during COVID and securing a non-COVID mRNA vaccine approval with mRESVIA, including a label expansion to certain higher-risk adults. Settlement of the lipid-nanoparticle patent dispute removes a major legal overhang, improving focus and visibility for launches and late-stage execution.
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development has...
MSI Reproductive Choices provides contraception and abortion services that enable women worldwide to choose their futures. Its mission is to ensure everyone, everywhere, has reproductive choice, and it delivers and expands high-quality contraception and abortion services around the world. Its 9,000 team members work across six continents, delivering reproductive healthcare and supporting people in making choices about their bodies and...
Doctify is a high-growth HealthTech company revolutionising the global healthcare market. Having expanded into 6 markets with an ambitious growth plan over the coming year. Doctify has developed a first-of-its-kind healthcare-specific patient feedback and review product allowing healthcare professionals to drive improvements in patient care on a daily basis. Our SaaS product allows healthcare providers to collect and digitize patient feedback and...
Covidence is a non-profit social enterprise and global SaaS platform dedicated to accelerating the creation of systematic reviews for the evidence community. It provides a collaborative workflow tool used by leading institutions to streamline citation screening, full-text review, risk of bias assessment, and data extraction, helping researchers transform scientific research into trustworthy and actionable summaries of knowledge.
The Walter and Eliza Hall Institute of Medical Research (WEHI) is a medical research institute dedicated to improving health outcomes through discovery, translation, and education. WEHI focuses on developing treatments for cancer, immune disorders, infections, and diseases of development and ageing, collaborating to make life-changing scientific discoveries that help people live healthier, longer lives.
Natural MedTech is manufacturing psychedelic medicines to unlock neurologic potential. We are building Australia’s leading pure-play psychedelic business, with differentiated IP, an experienced team, and a self-funding growth profile.
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
The International SOS Group of Companies is in the business of saving lives, protecting global workforces from health and security threats. We deliver customised health, security risk management and wellbeing solutions to fuel our clients’ growth and productivity. In the event of extreme weather, an epidemic or a security incident, we provide an immediate response providing peace of mind. Our...
Seer is a medical technology company on a mission to give people more control of their most valuable assets—their health and their time—by reimagining how and where they undergo long-term clinical monitoring. Seer's products and services are focused on solving the problems related to the early and accurate diagnosis of epilepsy. Seer’s flagship suite of technologies, offered through a provider...
We’re Medmate. Nice to meet you. We take the inconvenience and awkwardness out of pharmacy visits. Book a consultation with a doctor or get a script all online. It's fast, easy and convenient. Medmate was developed by doctors and pharmacists and born out of a desire to take the burden out of pharmacy shopping and make life that little bit...
MedHealth is a purpose-built collection of industry-leading health, medical, and employment brands that leverage diverse capabilities to deliver optimal health and employment outcomes for the people and communities they support.
Halaxy makes healthcare better all over the world. Halaxy is a platform for patients, practitioners and people everywhere, and provides: 1. Practice management software (EMR, billing and scheduling) for any practitioner of any profession in any practice anywhere in the world; 2. Searchable practitioner directories covering 50% of the English speaking world enabling people to find the right practitioner for...
Palla Pharma Limited is one of three licensed poppy processors in Australia, and the only Australian-owned company. It is one of only three companies globally that is vertically integrated from poppy growing through to tableting production. Palla Pharma has developed an innovative, efficient and environmentally-sustainable extraction and purification manufacturing process which allows the company to deliver a highly competitive pricing platform....
Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world....
